Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.93 and traded as low as $0.83. Atossa Therapeutics shares last traded at $0.84, with a volume of 552,183 shares changing hands.
Analyst Ratings Changes
Several brokerages have commented on ATOS. Ascendiant Capital Markets raised their price objective on Atossa Therapeutics from $7.00 to $7.25 and gave the company a "buy" rating in a report on Monday, April 21st. HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Atossa Therapeutics in a report on Wednesday, March 26th.
Read Our Latest Stock Report on ATOS
Atossa Therapeutics Price Performance
The stock has a 50 day moving average price of $0.73 and a 200-day moving average price of $0.92. The stock has a market capitalization of $125.31 million, a price-to-earnings ratio of -4.41 and a beta of 1.01.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. As a group, research analysts forecast that Atossa Therapeutics, Inc. will post -0.22 earnings per share for the current year.
Hedge Funds Weigh In On Atossa Therapeutics
A number of institutional investors have recently added to or reduced their stakes in ATOS. Gallagher Capital Advisors LLC purchased a new position in Atossa Therapeutics during the fourth quarter worth approximately $25,000. Millennium Management LLC purchased a new position in Atossa Therapeutics during the fourth quarter worth approximately $28,000. Two Sigma Advisers LP lifted its position in Atossa Therapeutics by 214.1% during the fourth quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock worth $40,000 after buying an additional 28,900 shares in the last quarter. Intech Investment Management LLC lifted its position in Atossa Therapeutics by 224.0% during the fourth quarter. Intech Investment Management LLC now owns 62,844 shares of the company's stock worth $59,000 after buying an additional 43,449 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in Atossa Therapeutics by 30.7% in the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company's stock valued at $68,000 after purchasing an additional 16,853 shares during the period. Hedge funds and other institutional investors own 12.74% of the company's stock.
Atossa Therapeutics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Further Reading
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
